Showing 4551-4560 of 7006 results for "".
- Accelerating CBD Research and the Importance of Rigorous Clinical Trialshttps://reachmd.com/news/accelerating-cbd-research-and-the-importance-of-rigorous-clinical-trials/2471689/In recent years, growing interest in CBD’s potential medical applications has spurred rapid research efforts. Companies like Atlantia Clinical Trials are leading the way by conducting rigorous clinical trials, ensuring that future therapeutic claims are firmly grounded in r
- Exploring the Cardiovascular Risks of Cannabis Use in Modern Societyhttps://reachmd.com/news/exploring-the-cardiovascular-risks-of-cannabis-use-in-modern-society/2471717/The widespread legalization of cannabis invites rigorous discussion about its implications for heart health. Emerging evidence connects cannabis use to a noteworthy increase in the likelihood of heart attack and stroke, even in younger, otherwise healthy adults.
- Bringing Cardiac Imaging to the Masses: A New Era in Heart Health Assessmenthttps://reachmd.com/news/bringing-cardiac-imaging-to-the-masses-a-new-era-in-heart-health-assessment/2471680/Recognized as a cornerstone in heart health evaluation, cardiac imaging is validated by recent Yale University research. These studies propose groundbreaking strategies to enhance access, improving detection of heart abnormalities and enabling more personalized treatments.<
- Nurturing Resilience: Building Healthy Self-Esteem in Childrenhttps://reachmd.com/news/nurturing-resilience-building-healthy-self-esteem-in-children/2471666/Empowering Young Minds for a Brighter Future An exhaustive review of current research underscores the pivotal role of fostering self-esteem in children to promote academic success, strong social bonds, and resilient behaviors. This piece offers practical strategies
- PN Therapeutic Pipeline Continues to Show Promisehttps://reachmd.com/news/PN-Therapeutic-Pipeline-Continues-Show-Promise/2471649/The US Food and Drug Administration (FDA) approval last year of nemolizumab for the treatment of adults with prurigo nodularis (PN) was likely only the beginning of a dramatically changing therapeutic landscape for that condition, Sonja Stander, MD, IFAAD, said at the 2025 American Academy of Der
- Understanding Skin Cancer Risk: The Impact of Severe Sunburns and Socioeconomic Factorshttps://reachmd.com/news/understanding-skin-cancer-risk-the-impact-of-severe-sunburns-and-socioeconomic-factors/2471644/A thorough investigation into the long-term effects of severe sunburns during youth reveals pronounced sociodemographic trends in sunburn prevalence. These insights are paving the way for tailored preventive strategies to mitigate skin cancer risk.
- New Tapinarof Data Promising for Children and Perhaps Morehttps://reachmd.com/news/New-Tapinarof-Data-Promising-Children-Perhaps-More/2471623/An analysis of the Phase 3 ADORING 3 study evaluating tapinarof cream, 1% once daily in adults and children 2 years of age and older with atopic dermatitis (AD) presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, demonstrated that AD disease activity re
- Unraveling the Link Between Chronic Stress and Stroke Risk in Womenhttps://reachmd.com/news/unraveling-the-link-between-chronic-stress-and-stroke-risk-in-women/2471500/Investigating the Gender-Specific Impact of Chronic Stress on Stroke Incidence Recent clinical research indicates a significant association between chronic stress and increased stroke risk among younger female adults. This article delves into the study findings, em
- The Looming Global Crisis: Overweight and Obesity Trends Towards 2050https://reachmd.com/news/the-looming-global-crisis-overweight-and-obesity-trends-towards-2050/2471458/A Forecast Reveals Over Half of Adults and One Third of Youth May Face Obesity by 2050 According to a recent analysis by the Global Burden of Disease Study BMI Collaborators published in The Lancet, projections indicate that more than half of th
- Biologics, JAKs, and More Cited as Potential Treatments for CPUOhttps://reachmd.com/news/Biologics-JAKis-More-Cited-Potential-Treatments-CPUO/2471552/New therapies for chronic pruritus of unknown origin (CPUO) could be close, Gil Yosipovitch, MD, said during his presentation, “What’s Best and What’s Next for Systemic Itch and CPUO” at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. “These are patients